1. Home
  2. PHAR vs HELP Comparison

PHAR vs HELP Comparison

Compare PHAR & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$10.16

Market Cap

793.4M

Sector

Health Care

ML Signal

HOLD

Logo Cybin Inc. Common Stock

HELP

Cybin Inc. Common Stock

HOLD

Current Price

$12.76

Market Cap

889.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAR
HELP
Founded
1988
N/A
Country
Netherlands
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
793.4M
889.9M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
PHAR
HELP
Price
$10.16
$12.76
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$38.33
★ $51.50
AVG Volume (30 Days)
33.8K
★ 1.7M
Earning Date
05-07-2026
07-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$10.04
N/A
Revenue Next Year
$2.51
N/A
P/E Ratio
$3,041.22
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.62
$3.76
52 Week High
$21.34
$15.15

Technical Indicators

Market Signals
Indicator
PHAR
HELP
Relative Strength Index (RSI) 38.04 52.20
Support Level $9.62 $11.68
Resistance Level $11.60 $14.75
Average True Range (ATR) 0.47 0.96
MACD -0.03 -0.20
Stochastic Oscillator 9.45 22.04

Price Performance

Historical Comparison
PHAR
HELP

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

Share on Social Networks: